

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

UNIVEC, INC.

9722 Groffs Mills Drive, Suite 116, Owings Mills, Maryland 21117

(443) 253-0194

www.univechealth.com

info@univechealth.com

SIC Code: 3841

Quarterly Report

For the period ending June 30, 2023 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

2,523,096,680 as of July 27, 2023

2,523,096,680 as of June 30, 2023

2,523,096,680 as of May 7, 2023

2,523,096,680 as of March 31, 2023

2,523,096,680 as of February 27, 2023

2,523,096,680 as of December 31, 2022

2,523,096,680 as of September 30, 2022

2,339,923,522 as of June 30, 2022

2,339,923,522 as of March 31, 2022

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

The Company is a Delaware corporation, incorporated on October 7, 1996, and the successor by merger to Univec, Inc., a New York corporation, incorporated on August 18, 1992. On March 1, 2014 the Company changed name to Univec Conglomerate, Inc.

On June 19, 2021 the Company changed name from Univec Conglomerate, Inc., to Univec, Inc., filed with the State of Delaware, Division of Corporations on June 21, 2021 file number 2670427

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The Company's current status with the State of Delaware is Active.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

9722 Groffs Mills Drive, Suite 116, Owings Mills, MD 21117

The address(es) of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Continental Stock Transfer & Trust Company
Phone: (212) 509-4000
Email: eyoung@continentalstock.com
Address: 1 State Street, 30th Floor, New York, NY 10004-1561

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>UNVC</u>
Exact title and class of securities outstanding:	<u>Common</u>
CUSIP:	<u>91335U108</u>
Par or stated value:	<u>\$0.001</u>
Total shares authorized:	<u>5,000,000,000</u> as of date: <u>06/30/2023</u>

Total shares outstanding: 2,523,096,680 as of date: 06/30/2023

All additional class(es) of publicly quoted or traded securities (if any):

Trading symbol: N/A
Exact title and class of securities outstanding: _____
CUSIP: _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____

Trading symbol: N/A
Exact title and class of securities outstanding: _____
CUSIP: _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____

Other classes of authorized or outstanding equity securities:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security: _____
CUSIP (if applicable): _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding (if applicable): _____ as of date: _____
Total number of shareholders of record (if applicable): _____ as of date: _____

Exact title and class of the security: N/A
CUSIP (if applicable): N/A _____
Par or stated value: N/A _____
Total shares authorized: N/A _____ as of date: _____
Total shares outstanding (if applicable): N/A _____ as of date: _____
Total number of shareholders of record (if applicable): N/A _____ as of date: _____

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

The Company did not pay dividends. Common shares voting rights is one (1) vote per share. no preemption rights in bylaws

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The Company did not pay dividends. Preferred shares have one hundred (100) votes per shares. No conversion, liquidation and redemption or sinking fund provisions set forth in the bylaws.

3. Describe any other material rights of common or preferred stockholders.

No other material rights not disclosed above for common or preferred stockholders.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

No modifications have occurred over the reporting period covered by this report

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

[space intentionally left blank]

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End:									
Opening Balance									
Date <u>December 31, 2019</u>		Common:	1,179,023,522						
		Preferred:	3,743,900						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
05/09/21	New issuance	1,100,000,000	Common	0.001	No	David Dalton Bridgeview Capital Group /	Debt conversion	Restricted	Exempt
12/17/21	New issuance	60,900,000	Common	0.001	Yes	Benjamin Mayer - Managing Member	Services	Unrestricted	
03/01/22	New issuance	1,256,100	Preferred	0.033	No	David Dalton	Debt conversion	Preferred	Exempt
09/12/22	New issuance	183,173,158	Common	0.0095	No	David Dalton	Debt conversion	Restricted	Exempt
Shares Outstanding on Date of This Report:									
Ending Balance Ending Balance:									

Date	Common:	2,523,096,680	
<u>03/31/2023</u>	Preferred:	5,000,000	

Example: A company with a fiscal year end of December 31st, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2021 through December 31, 2022 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

N/A

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☒ Yes: ☐ (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

N/A

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.
(Please ensure that these descriptions are updated on the Company's Profile on www.otcmarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

On September 27, 2005 the Company signed the required information sheet with the facility Addiction Treatment Services at Hopkins Bayview Mason F Lord Building 6th Floor East 4940 Eastern Avenue. The process covered by such information sheet never was activated, however Management is trying to get this process operative, which may create a very important market for Univec, Inc., and also a significant benchmark mode for the Company.

B. List any subsidiaries, parent company, or affiliated companies.

At the time of this filing the Company has no subsidiaries, parents or affiliated companies.

C. Describe the issuers' principal products or services.

Pharmaceuticals products and Services

5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company's indicated address is an usable mangement suite.

6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more that 5% of any class of the issuers securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Dr. David Dalton</u>	<u>Chairman & CEO</u>	<u>Pikesville, MD</u>	<u>1,403,122,537</u>	<u>Common</u>	<u>55.61%</u>	<u>N/A</u>
<u>Lamont Ellis</u>	<u>President</u>	<u>Baltimore, MD</u>	<u>None</u>	<u>N/A</u>	<u>0.00%</u>	<u>N/A</u>
<u>Chris Farnsworth</u>	<u>VP & Director</u>	<u>Baltimore, MD</u>	<u>None</u>	<u>N/A</u>	<u>0.00%</u>	<u>N/A</u>

<u>Kenneth Grant</u>	<u>Director</u>	<u>Owings Mills, MD</u>	<u>None</u>	<u>N/A</u>	<u>0.00%</u>	<u>N/A</u>
<u>Lauren Herron</u>	<u>Vice-president</u>	<u>Baltimore, MD</u>	<u>None</u>	<u>N/A</u>	<u>0.00%</u>	<u>N/A</u>

7) Legal/Disciplinary History

A. Identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Patrick Ryan Morris
Address 1: 28 Laight Street
Address 2: 2nd Floor, New York 10013
Phone: (646) 692-4012
Email: prm@patrickmorrislaw.com

Accountant or Auditor

Name: Richard Blickstein
Firm: Richard Blickstein Accounting and Taxes, Inc.

Address 1: 1964 Deer Path Road
Address 2: Harrisburg, PA 17110
Phone: (771) 329-8354
Email: rblick3745@aol.com

Investor Relations

Name: None
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

Twitter: N/A
Discord: N/A
LinkedIn: N/A
Facebook: N/A
[Other] N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: N/A
Firm: N/A
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☐ IFRS
☒ U.S. GAAP

B. The following financial statements were prepared by (name of individual)²:

Name: Richard Blickstein
Title: CPA
Relationship to Issuer: Accountant

Describe the qualifications of the person or persons who prepared the financial statements: Graduated from George Washington University with a Major in Commercial Science in 1972. Worked for Gross, Heller and Rapaport CPA's. Own accounting practice since 1974.

² The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

[space intentionally left blank]

UNIVEC, Inc.
Condensed Balance Sheets
(Unaudited)

	June 30, 2023 (Unaudited)	December 31, 2022 (Unaudited)
ASSETS		
Current assets		
Cash and cash equivalents	\$ -	\$ -
Accounts Receivable	11,852	4,725
Other Assets	-	-
Total current assets	<u>11,852</u>	<u>4,725</u>
PROPERTY & EQUIPMENT, NET (net of \$11,562 and \$ 8,620 depreciation as June 30, 2023 and December 31, 2022 respectively)	25,570	28,512
Other noncurrent assets		
Expenses paid in advance	486,185	1,337,009
Total Other Noncurrent Assets	<u>511,755</u>	<u>1,365,521</u>
Total assets	<u><u>\$ 523,607</u></u>	<u><u>\$ 1,370,246</u></u>
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)		
Current liabilities:		
Accounts payable	276,188	236,586
Bank overdraft	-	-
Related party short-term loan	12,103	13,189
Payroll liabilities	12,966,026	12,452,470
Accrued employees' benefits	84,887	21,222
Total current liabilities	<u>13,339,204</u>	<u>12,723,467</u>
Long Term Liabilities		
Long-term loans	71,892	71,892
Related party long-term loans	1,081,324	1,050,308
Total Long-Term Liabilities	<u>1,153,216</u>	<u>1,122,200</u>
Total liabilities	<u>14,492,420</u>	<u>13,845,667</u>
Preferred Stock		
Authorized 5,000,000 shares as of June 30, 2023, and December 31, 2022 issued and outstanding 5,000,000 par value \$0.001	5,000	5,000
Common Stock		
Authorized 5,000,000,000 shares par value \$0.001. 2,523,096,680 and 2,523,096,680 issued and outstanding as of June 30, 2023, and as of December 31, 2022, respectively	2,523,097	2,523,097
Additional Paid-in-Capital	14,804,670	14,804,670
Retained Earnings (loss)	(31,301,580)	(29,808,188)
Total shareholders' equity (deficit)	<u>(13,968,813)</u>	<u>(12,475,421)</u>
Total liabilities and shareholders' equity (deficit)	<u><u>\$ 523,607</u></u>	<u><u>\$ 1,370,246</u></u>

See accompanying notes to the condensed unaudited financial statements.

[space intentionally left blank]

UNIVEC, Inc.

Condensed Statement of Operations
(Unaudited)

	For the Three Months Ended on June 30		For the Six-Months Ended on June 30	
	2023 (Unaudited)	2022 (Unaudited)	2023 (Unaudited)	2022 (Unaudited)
REVENUES	7,006	\$ 13,500	\$ 11,852	\$ 22,320
COST OF SALES	6,514	12,600	11,012	20,664
GROSS PROFIT	492	900	840	1,656
General and Administrative expenses	823,164	657,701	1,479,324	1,317,632
Depreciation Expenses	1,479	1,463	2,942	2,926
Total operating expense	824,643	659,164	1,482,266	1,320,558
Profit (Loss) from operations	(824,151)	(658,264)	(1,481,426)	(1,318,902)
OTHER INCOME (EXPENSES)				
Interest Expense	(5,620)	(2,280)	(10,897)	(4,576)
Interest Income				
Other Operational Income (expenses)	(1,069)		(1,069)	1,729
Total other income (expense)	(6,689)	(2,280)	(11,965)	(2,847)
Income (Loss) from continuing operations	(830,839)	(660,544)	(1,493,392)	(1,321,749)
NET INCOME (LOSS)	\$ (830,839)	\$ (660,544)	\$ (1,493,392)	\$ (1,321,749)
Net income (loss) per share applicable to common stockholders - basic	\$ (0.00)	(0.00)	\$ (0.00)	\$ (0.00)
Net income (loss) per share applicable to common stockholders - diluted	\$ (0.00)	(0.00)	\$ (0.00)	\$ (0.00)
Weighted average number of common shares outstanding - basic	2,523,096,680	2,339,923,522	1,179,023,522	2,339,923,522
Weighted average number of common shares outstanding - diluted	2,523,096,680	2,339,923,522	1,179,023,522	2,339,923,522

See accompanying notes to the condensed unaudited financial statements.

Statements of Shareholders' Equity (Deficit) for the Periods Ended on December 31, 2020, through June 30, 2023

(Unaudited)

	Common Shares	Common Stock	Preferred Shares	Preferred Stock	Additional Paid in Capital	Other Interest	Accumulated Deficit	Total Shareholders' Deficit
BALANCE, December 31, 2020	1,179,023,522	\$ 1,179,024	3,743,900	\$ 3,744	\$ 10,392,744	\$ 1,100,000	\$ (25,800,639)	(13,125,127)
Net Income (loss)							(305,588)	(305,588)
BALANCE, March 31, 2021	1,179,023,522	\$ 1,179,024	3,743,900	\$ 3,744	\$ 10,392,744	\$ 1,100,000	\$ (26,106,227)	\$ (13,430,715)
Shares due to conversion	1,100,000,000	1,100,000				(1,100,000)		-
Net Income (loss)							(319,529)	(319,529)
BALANCE, June 30, 2021	2,279,023,522	\$ 2,279,024	3,743,900	\$ 3,744	\$ 10,392,744	\$ -	\$ (26,425,756)	\$ (13,750,243)
Net Income (loss)							(294,038)	(294,038)
BALANCE, September 30, 2021	2,279,023,522	\$ 2,279,024	3,743,900	\$ 3,744	\$ 10,392,744	\$ -	\$ (26,719,794)	\$ (14,044,281)
Shares for services	60,900,000	60,900			2,856,210			2,917,110
Net Income (loss)							(420,590)	(420,590)
BALANCE, December 31, 2021	2,339,923,522	\$ 2,339,924	3,743,900	\$ 3,744	\$ 13,248,954	\$ -	\$ (27,140,384)	\$ (11,547,761)
Shares due to conversion			1,256,100	\$ 1,256	\$ 40,195			41,451
Net Income (loss)							(661,205)	(661,205)
BALANCE, March 31, 2022	2,339,923,522	\$ 2,339,924	5,000,000	\$ 5,000	\$ 13,289,149	\$ -	\$ (27,801,589)	\$ (12,167,516)
Shares due to conversion					(41,451)		(1,727)	(43,178)
Net Income (loss)							(660,545)	(660,545)
BALANCE, June 30, 2022	2,339,923,522	2,339,924	5,000,000	5,000	13,247,698	-	(28,463,861)	(12,871,239)
Shares due to conversion	183,173,158	183,173			1,556,972			1,740,145
Net Income (loss)							(674,118)	(674,118)
BALANCE, September 30, 2022	2,523,096,680	2,523,097	5,000,000	5,000	14,804,670	-	(29,137,979)	(11,805,213)
Shares due to conversion								-
Net Income (loss)							(670,208)	(670,208)
BALANCE, December 31, 2022	2,523,096,680	2,523,097	5,000,000	5,000	14,804,670	-	(29,808,188)	(12,475,421)
Shares due to conversion								-

Net Income (loss)							(662,553)	(662,553)
BALANCE, March 31, 2023	2,523,096,680	2,523,097	5,000,000	5,000	14,804,670	-	(30,470,741)	(13,137,974)
Shares due to conversion								-
Net Income (loss)							(830,839)	(830,839)
BALANCE, June 30, 2023	2,523,096,680	2,523,097	5,000,000	5,000	14,804,670	-	(31,301,580)	(13,968,814)

See accompanying notes to the condensed unaudited financial statements.

[space intentionally left blank]

UNIVEC, Inc.
Condensed Statements of Cash-Flows
(Unaudited)

	For the Six Months Ended on June 30	For the Twelve- Months ended on December 31
	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Income (Loss)	\$ (1,493,392)	\$ (1,339,745)
Adjustment to reconcile net income (loss) to net cash provided operating activities:		
Depreciation and amortization expense	2,942	
Change in operating assets and liabilities:		
Accounts receivable	(7,127)	(11,340)
Inventory	-	-
Assets write off		
Other assets write off		
Notes Receivable	-	-
Other current assets	-	(1,458,555)
Security Deposits	-	-
Accounts payable and accrued expenses	39,602	182,477
Adjustment		-
Commitments	-	(1,100,000)
Payroll liability	513,556	907,112
Accrued employees benefits	63,665	84,886
Other assets	850,824	(1,337,009)
Other payables	-	89,874
Deferred revenue	-	-
Net cash provided by operating activities	<u>(29,930)</u>	<u>(3,982,300)</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Cash paid for assets acquisition	-	(34,470)
Net cash used in investing activities	<u>-</u>	<u>(34,470)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Shares issued due to conversion	-	-
Shares issued for services		2,917,110
Bank overdraft	-	
Proceeds from notes payable	-	
Proceeds from common stock issuance	-	1,100,000
Proceeds from preferred stock issuance	-	
Financial Loans Payable	29,930	-
Net Cash provided by financing activities	<u>29,930</u>	<u>4,017,110</u>

NET CHANGE IN CASH	0	-
CASH, beginning of period	-	-
CASH, end of period	\$ 0	\$ -

NON-CASH INVESTING AND FINANCING ACTIVITIES

Issuance of shares of common stock for convertible debt	\$ -	\$ 11,000
Issuance of shares of common stock for conversion of preferred stock	\$ -	\$ -
Issuance of shares for services	\$ -	\$ 183,173
Loans issued to acquire fixed assets	\$ -	\$ -
Loan payable paid by related party	\$ -	\$ -
	-	

SUPPLEMENTAL DISCLOSURES:

Cash paid for income taxes	\$ -	\$ -
Cash paid for interest	\$ 10,897	\$ -

See accompanying notes to the condensed unaudited financial statements.

[space intentionally left blank]

Univec, Inc

Notes to the Condensed Financial Statements

June 30, 2023

(Unaudited)

NOTE 1: NATURE OF ORGANIZATION

The Company is a Delaware corporation, incorporated on October 7, 1996, and the successor by merger to Univec, Inc., a New York corporation, incorporated on August 18, 1992.

On March 1, 2014 the Company changed name to Univec Conglomerate, Inc.

On June 19, 2021 the Company changed name from Univec Conglomerate, Inc., to Univec, Inc., filed with the State of Delaware, Division of Corporations on June 21, 2021 file number 2670427

NOTE 2: GOING CONCERN

These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. As of June 30, 2023, and December 31, 2022, the Company has an accumulated deficit of \$ 31,301,580 and \$ 29,808,188 since inception, respectively. This raises substantial doubt about the Company's ability to continue as a going concern.

The extent of the impact of the coronavirus ("COVID- 19") outbreak on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions, and the impact of COVID- 19 on the overall economy, all of which are highly uncertain and cannot be predicted. If the overall economy is impacted for an extended period, the Company's future operating results may be materially adversely affected.

Management's plans include raising capital through the equity markets to fund operations and eventually generate revenue through its business; however, there can be no assurance that the Company will be successful in such activities. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3: SUMMARY OF SIGNIFICANT ACCOUNT POLICIES

Principles of Consolidation

The accompanying consolidated financial statements of Univec, Inc., include its own operation, the Company has no subsidiaries.

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for financial statements and with the instructions to Regulation S-X of the United States Securities and Exchange Commission ("SEC"). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for annual financial statements.

In the opinion of the Company's management, the accompanying unaudited condensed financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2023, and December 31, 2022, and the results of operations and cash flows for the periods presented. The results of operations for the three months ended June 30, 2023, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company's Annual Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines for the year ended December 31, 2022, filed hereto. The Company filed its Annual Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines and in compliance to the Amended SEC Rule 15c2-11.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported in the consolidated financial statements.

Carrying Value, Recoverability and Impairment of Long-Lived Assets

OTC Markets Group Inc.

OTC Pink Basic Disclosure Guidelines (v4.0 January 1, 2023)

Page 18 of 26

The Company's long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

Cash and Cash Equivalents

The Company considers all investments with an original maturity date of three months or less to be cash equivalents. The Company had cash in the amount of \$ 0 and \$ 0 as of June 30, 2023, and December 31, 2022, respectively.

Accounts Receivable and Allowance for Doubtful Accounts

Account receivables are recorded at the invoiced amount, net of an allowance for doubtful accounts. The Company performs on-going credit evaluations of its customers and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by the review of their current credit information; and determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and general economic conditions that may affect a client's ability to pay.

Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company determines when receivables are past due, or delinquent based on how recently payments have been received.

The Company has net \$ 11,852 and \$ 4,725 in accounts receivable, and another receivable, on June 30, 2023, and December 31, 2022, respectively.

Property and Equipment

Property and equipment will be recorded at cost when the case may be. Expenditures for major additions and betterments will be capitalized when it applies.

Maintenance and repairs will be charged to operations as incurred. Depreciation of property and equipment will be computed by the straight-line method (after considering their respective estimated residual values) over the estimated useful lives of the respective assets as follows:

Fixed Asset	Estimated Useful Life (Years)
Building	39
Improvements	5
Furniture and office equipment	7
Computer Equipment	7
Vehicles	5

Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation will be removed from the accounts and any gain or loss will be reflected in statements of operations. During the Three-months ended June 30, 2023, and December 31, 2022, respectively, the Company equipment, resulting in net (net of \$11,562 and \$8,620 depreciation as June 30, 2023, and December 31, 2022, respectively) fixed assets of \$ 25,570 and \$ 28,512.

Description	Total Acquisition Cost	Span of Life (years)	Depreciation			Accumulated as of June 30, 2023	Net Value June 30, 2023
			Accumulated as of December 31, 2022	2023-Q1 March 31, 2023	2023-Q2 June 30, 2023		
Office Equipment	\$ 20,000	7	\$ 4,280	\$ 705	\$ 712	\$ 5,696	\$ 14,304
Computers	6,132	7	1,312	216	\$ 218	1,746	\$ 4,386
Vehicle	11,000	5	3,029	542	\$ 548	4,120	\$ 6,880
Total	\$37,132		\$ 8,620	\$ 1,463	\$ 1,479	\$ 11,562	\$ 25,570

Beneficial Conversion Feature

If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature will be characterized as a beneficial conversion feature (“BCF”). A BCF will be recorded by the Company as a debt discount pursuant to ASC 470-20 *Debt with Conversion and Other Options*. In those circumstances, the convertible debt will be recorded net of the discount related to the BCF, and the Company will amortize the discount to interest expense over the life of the debt using the effective interest method.

Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt under ASC 815 Derivatives and Hedging to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument will be evaluated under ASC 470-20 *Debt with Conversion and Other Options* for consideration of any beneficial conversion features.

Derivative Financial Instruments

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company will use the Black-Scholes option-pricing model, when applicable. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and, further, if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

Once determined, derivative liabilities will be adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, will be also valued using the Black Scholes option-pricing model.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in the absence of a principal, most advantageous market for the specific asset or liability.

GAAP provides for a three-level hierarchy of inputs to valuation techniques used to measure fair value, defined as follows:

Level 1: Inputs that are quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity can access.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability, including:

- quoted prices for similar assets or liabilities in active markets.
- quoted prices for identical or similar assets or liabilities in markets that are not active.
- inputs other than quoted prices that are observable for the asset or liability; and
- inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Inputs that are unobservable and reflect management’s own assumptions about the inputs market participants would use in pricing the asset or liability based on the best information available in the circumstances (e.g., internally derived assumptions surrounding the timing and amount of expected cash flows).

Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of June 30, 2023, and December 31, 2022:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Derivative Liability				
December 31, 2022	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>
June 30, 2023	<u><u> </u></u>	<u><u> </u></u>	<u><u>\$ -</u></u>	<u><u>\$ -</u></u>

Revenue Recognition

Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) standard update ASU 2014-09, “Revenue from Contracts with Customers,” (“Topic 606”) which provides a principles-based, five-step approach to measure and recognize revenue from contracts with customers. Revenue is recognized when the following criteria are met:

- Identification of the contract, or contracts, with a customer;
- Identification of the performance obligations in the contract;
- Determination of the transaction price;
- Allocation of the transaction price to the performance obligations in the contract; and
- Recognition of revenue when, or as, we satisfy performance obligation.

The adoption of this guidance did not have a material impact on the Company’s consolidated statements of operations, cash flows, shareholders’ equity (deficit), or balance sheets as of the adoption date.

The Company does generate revenues during the three-months ended June 30, 2023. Revenues generated during the three-months ended June 30, 2023, and twelve-months period ended on December 31, 2022, totaled \$ 7,006, \$11,852 and \$ 33,165 respectively, and were included in net loss from continued operations in the accompanying statements of operations.

We periodically review for any expected period of substantial involvement under the agreements that provide for non-refundable up-front payments and fees. If applicable, we will adjust the amortization periods when appropriate to reflect changes in assumptions relating to the duration of our expected involvement.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Additionally, the recognition of future tax benefits, such as net operating loss carryforwards, is required to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are determined using enacted tax rates expected to apply to taxable income in the years in which the assets and liabilities are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the period that includes the enactment date.

In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such asset is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.

The Company files income tax returns in Maryland, which are subject to examination by the tax authorities in these jurisdictions. Generally, the statute of limitations related to the Company’s federal and state income tax return is three years. The state impact of any federal changes for prior years remains subject to examination for a period up to five years after formal notification to the states.

Management has evaluated tax positions in accordance with ASC 740, *Income Taxes*, and has not identified any significant tax positions, other than those disclosed. All the Company’s tax years since inception remain subject to examination by Federal and State jurisdictions.

Earnings Per Share

	For the Six-Months Ended on June 30 2023 (Unaudited)	For the Twelve-Months ended on December 31 2022 (Unaudited)
Numerator		
Net income (loss) applicable to common shareholders	\$ (1,493,392)	\$ (2,666,076)
Denominator		
Weighted average common shares outstanding, basic	2,523,096,680	1,179,023,522
Convertible preferred stock	-	-
Convertible promissory notes	-	-

Weighted average common shares outstanding, diluted	2,523,096,680	1,179,023,522
Net Income per share - Basic	\$ (0.00)	\$ (0.00)
Income per shares - Diluted	\$ (0.00)	\$ (0.00)

Basic net income per common share (“*Basic EPS*”) excludes dilution and is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“*Diluted EPS*”) reflects the potential dilution that could occur if stock options or other contracts to issue shares of common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

NOTE 5:

RELATED PARTY LOANS

For the period ended on June 30, 2023, and December 31, 2022, the Company has debt of \$12,966,026 and 12,452,470 respectively. Having as beneficiaries to Dr. David Dalton and Mr. Richard Blickstein. Also, the Company has Long-Term Related Party Loans, in the amount of for the period ended on June 30, 2023, and December 31, 2022, \$ 1,081,324 and \$1,050,308 respectively.

NOTE 6: OTHER LIABILITIES

Management is evaluating the status for payroll taxes, which may be accrued along these past years, by getting legal counsel and therefore a legal opinion over the matter, and if the case may will record all adjustment accordingly.

Accounts Payable

The Company enjoys terms for payments to its vendors, on traditional purchases the accounts payable balance, is \$ 276,188 and \$ 236,586 as of June 30, 2023, and December 31, 2022, respectively.

NOTE 7: EQUITY

On June 11, 2021, the Company issued one billion one hundred million (1,100,000,000) of restricted shares of common stock to Dr. David Dalton as his conversion of \$11,000 on the Company’s debt of Accrued employees benefits deducted on January 3, 2016, dated on which was that conversion submitted to the transfer agent.

On August 30, 2021 the Company issued an Irrevocable Stock Power to Bridgeview Capital Group, for 60,900,000 shares of common stock. On December 17, 2021, Bridgeview Capital Group, received the 60,900,000 shares Batch #: 1132053, and accordingly to ASC 718-10-50-1 the following information is disclosed: (a) The method of estimating the fair value of the equity: the Company valued these shares at the adjusted closing market price for such date, which was \$0.04790, (b) The nature and terms: the related agreement established payment of \$820,000 in monthly installments of \$35,000 the Company has no resources to satisfy this needed services, therefore the entire amount was settled on common stock shares of par value \$0,001 but at \$0.01379, notwithstanding the foregoing the Company understand that fair market value was as disclosed item (a) above in this paragraph, (c) The effect of compensation cost arising from share-based payment: the most significant effect was getting the services without any cash disbursement, (d) The cash flow effects resulting from share-based payment, was essentially positive in an amount of \$35,000 monthly basis.

On March 1, 2022, Dr. David Dalton converted \$41,451.30 of the Company debt due to Accrued employees’ benefits from prior periods into 1,256,100 preferred shares par value \$0.001 at \$0.033 per shares.

On August 30, 2022, Dr. David Dalton converted \$1,740,145 total employment contract benefits for prior periods. The 183,173,158 fully paid and nonassessable shares for this conversion were valued at 110% of the stock price ending 08/30/2022 \$0.0095

NOTE 8: COMMITMENTS AND CONTINGENCIES.

During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with ASC 450-20-50, *Contingencies*. The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals. As of June 30, 2023, and December 31, 2022, the Company is not aware of contingent liabilities or outstanding lawsuits against the Company.

NOTE 9: SUBSEQUENT EVENTS AFTER JUNE 30, 2023

The Company has evaluated subsequent events that occurred through the date these financial statements were issued, there is no subsequent events.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

D. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

On September 27, 2005 the Company signed the required information sheet with the facility Addiction Treatment Services at Hopkins Bayview Mason F Lord Building 6th Floor East 4940 Eastern Avenue. The process covered by such information sheet never was activated, however Management is trying to get this process operative, which may create a very important market for Univec, Inc., and also a significant benchmark mode for the Company.

E. Please list any subsidiaries, parents, or affiliated companies.

At the time of this filing the Company has no subsidiaries, parents or affiliated companies.

F. Describe the issuers' principal products or services.

Pharmaceuticals products and Services

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company's indicated address is an usable mangement suite.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Dr. David Dalton</u>	<u>Chairman & CEO</u>	<u>Pikesville, MD</u>	<u>1,403,122,537</u>	<u>Common</u>	<u>55.61%</u>	<u>N/A</u>
<u>Dr. David Dalton</u>	<u>Chairman & CEO</u>	<u>Pikesville, MD</u>	<u>5,000,000</u>	<u>Preferred</u>	<u>100%</u>	<u>N/A</u>
<u>Lamont Ellis</u>	<u>President</u>	<u>Baltimore, MD</u>	<u>=</u>	<u>N/A</u>	<u>0.00%</u>	<u>N/A</u>
<u>Chris Farnsworth</u>	<u>VP & Director</u>	<u>Baltimore, MD</u>	<u>=</u>	<u>N/A</u>	<u>0.00%</u>	<u>N/A</u>
<u>Kenneth Grant</u>	<u>Director</u>	<u>Owing Mills, MD</u>	<u>=</u>	<u>N/A</u>	<u>0.00%</u>	<u>N/A</u>
<u>Lauren Herron</u>	<u>Vice-president</u>	<u>Baltimore, MD</u>	<u>=</u>	<u>N/A</u>	<u>0.00%</u>	<u>N/A</u>

8) Legal/Disciplinary History

C. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

3. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

4. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

9. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

10. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

D. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Patrick Ryan Morris
Firm: Morris Legal Corp.
Address 1: 28 Laight Street
Address 2: 2nd Floor, New York 10013
Phone: (646) 692-4012
Email: prm@patrickmorrislaw.com

Accountant or Auditor

Name: Richard Blickstein
Firm: Richard Blickstein Accounting and Taxes, Inc.
Address 1: 1964 Deer Path Road
Address 2: Harrisburg, PA 17110
Phone: (771) 329-8354
Email: rblick3745@aol.com

Investor Relations

Name: None
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement.** This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: None
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

[page intentionally left blank]

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Dr. David Dalton certify that:

1. I have reviewed this Disclosure Statement for Univec, inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 11th, 2023 [Date]

/s/ David Dalton [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Dr. David Dalton certify that:

1. I have reviewed this Disclosure Statement for Univec, inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 11th, 2023 [Date]

/s/ David Dalton [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")